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Objectives: In the West, stent grafts for endovascular repair of thoracic aortic aneurysms have been commercially available
for several years, whereas in Japan, a manufactured stent graft was not approved for this application until March 2008.
Nevertheless, endovascular thoracic intervention began to be performed in Japan in the early 1990s, with homemade
devices used in most cases. Many researchers have continued to develop homemade devices. We have participated in joint
design and assessment efforts with a stent graft manufacturer, focusing primarily on fenestrated stent grafts used in
repairs at the distal arch, a site especially prone to aneurysm.
Methods: From 1995 to February 2008, we performed about 1100 endovascular procedures to treat thoracic aortic
aneurysms and 682 cases were performed at Tokyo Medical University. In 435 out of 682 the aneurysm was located in
the area from the distal arch to the proximal descending aorta. Fenestrated stent grafts were inserted in 288 cases.
Computed tomography scans were performed at 3, 6, and 12 months postoperatively and annually thereafter.
Results: The initial success rate in the entire series was 95.2%. Complications included 26 cerebral infarctions (3.8%), six
of which (0.9%) resulted in serious paralysis and changes in consciousness. Among patients who received fenestrated stent
grafts, paraplegia occurred in 2.6%, aortic injury in 1.2%, and iliofemoral artery injury in 6.0%. No complications resulted
from occlusion of aortic arch branches. At>2 years after intervention, aneurysm diameter was reduced in 62% of patients,
33% had no change, and 5% had a diameter enlargement. The stent graft complication rate during follow-up was 8.4%,
the device fracture rate was 1.4%, and the device migration rate was 7%. The 5-year survival rate was 62.4%, with
follow-up in 96.8% of the patients.
Conclusion:Endovascular repair has promising results in the descending thoracic aortic region, although some stent grafts
and their delivery systems can still be improved. Additional commercial developments and available stent grafts designed
for use in the distal arch are urgently needed. (J Vasc Surg 2008;48:24S-29S.)Aortic replacements using synthetic vascular grafts have
historically been the primary options for treatment of tho-
racic aortic aneurysms, but such procedures have been
extremely invasive. Thus, minimally invasive methods for
managing these lesions have been sought, with the aim of
improving outcomes. Most interest has focused on thoracic
endovascular aneurysm repair (TEVAR) as the principal
minimally invasive alternative to open surgery. In Japan,
commercially manufactured TEVAR stent grafts were ap-
proved only recently, finally initiating a shift from the
extensive use of homemade prostheses.
Although the number of TEVAR procedures has in-
creased sharply worldwide, the development of manufac-
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24Stured devices for treating aneurysms in the distal arch has
lagged, and no stent grafts specifically approved for this
purpose are currently marketed. At our institution, we have
used homemade stent grafts to treat distal arch aneurysms
for several years. We shared our experience with a commer-
cial manufacturer for a joint effort to develop fenestrated
stent grafts and initiate a formal clinical investigation of
these devices.
HISTORY OF TEVAR
Endovascular aortic repair began in 1969 with an ex-
perimental study in dogs by Dotter.1 The first reported
clinical studies were by Parodi et al,2 who performed suc-
cessfully endovascular treatment of abdominal aortic aneu-
rysms in Argentina in 1991, and byDake et al3 andMitchell
et al,4 who described TEVAR in the United States in the
mid-1990s. In Japan, reports of clinical studies of TEVAR
started to appear in the late 1990s, and use of this proce-
dure has grown ever since then, along with recognition of
its efficacy.5-7 The results of numerous clinical TEVAR
investigations throughout the world have been published
since 2000.8-17
Commercially manufactured stent grafts approved by
the United States Food and Drug Administration and the
European health authorities for use in TEVAR have been
available for several years. In Japan, however, the Ministry
of Health, Labor and Welfare did not approve a TEVAR
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Thoracic Endoprosthesis (W. L. Gore & Assoc, Flagstaff,
Ariz), consists of an expanded polytetrafluoroethylene
(ePTFE) graft and a nitinol stent.13,17
The TAG device has been found to provide results
superior to those obtained with open surgical repair of
thoracic aortic aneurysms15,17 and was reported by its
manufacturer to have the following worldwide rates of
complications through January 19, 2007: migration, 0.4%;
aneurysm rupture, 0.8%; conversion to open surgery, 0.4%;
and requirement for additional stent graft insertion,
1.5%.16
In April 2008 a formal clinical study of another TEVAR
prosthesis, it is called the Najuta endograft (Kawasumi
Laboratories, Tokyo, Japan), began in Japan. The Najuta is
a fenestrated device that preserves blood flow through
branches of the aortic arch and is especially suitable for
treating distal arch aneurysms. We have been involved in
the development of this prosthesis and are participating in
the clinical study.
We performed our first TEVAR in 1995 and have used
the procedure to treat about 1100 patients, including pa-
tients at other institutions, in the past 13 years. We have
also been involved in efforts to improve TEVAR stent
grafts, delivery system, and procedural techniques. Because
manufactured TEVAR prostheses were not approved in
Japan until recently, we and others have primarily used
homemade stent grafts, usually devices created by suturing
a vascular graft material such as polyester fabric or ePTFE
membrane to a self-expanding Gianturco Z stent (Cook
Medical, Bloomington, Ind) or a Matsui-Kitamura stent.
Inoue stent grafts have also been used.
The homemade stent grafts created at our institution
are individually designed to fit the aortic configuration of
each patient. Our aim has been to use diverse engineering
methods to make devices that can be introduced into
tortuous arteries. Special attention is given to the design of
the stent joint sections, the graft covering, and the delivery
system (introducer sheath) so that the stent graft will
function as a completely integrated system (Fig 1).
The delivery system includes a stabilizer that facilitates
safe and steady advancement of the delivery sheath, thereby
reducing vessel injuries and thromboembolisms and en-
abling reliable placement of the stent graft in the presence
of unstable blood kinetics. Recently we have begun to
repair aneurysms in the distal aortic arch by introducing a
stent graft from the ascending aorta and preserving blood
flow into the arch branches by means of fenestrations in the
device (Najuta endograft; Fig 2). Enormous aortic mor-
phologic data from our experience with the fenestrated
Najuta stent graft have been analyzed and expressed as
patterns. Najuta devices are currently being used in the first
clinical study of TEVAR in Japan.
PRETREATMENT ASSESSMENT
Pretreatment imaging studies are essential for safe and
accurate stent graft deployment in a TEVAR procedure.
Computed tomography (CT) scanning, angiography, ul-trasonography, and magnetic resonance angiography have
all been used for pretreatment assessment, but CT scanning
is preferable because it can be used for multiple purposes
and it is noninvasive. Three-dimensional (3D) CT scanning
is ideal. Angiography, however, provides as much informa-
tion as 3D CT scanning and is essential for selecting the
optimal stent graft for use in a specific patient on the basis of
its overall shape, its length, and the connecting angle of the
stent frame.
INDICATIONS FOR TREATMENT
Anatomic criteria. The anatomy of the aorta must be
suitable for endografting. Morphologic criteria for TEVAR
vary among facilities. At our institution, we do not perform
TEVAR if one or more of the following characteristics are
observed on imaging:
● the segment of healthy aorta is 15 mm from the
origin of the major aortic branch vessels (eg, the ca-
rotid, celiac, mesenteric, and renal arteries) to the start
or end of an aneurysm;
● the healthy aorta against which the stent graft would
be seated is severely tortuous or calcified;
● the diameter of the aortic neck is either 38 mm or
10 mm;
● the inferior mesenteric artery and both internal iliac
arteries are all occluded;
● the aorta, iliac, or femoral arteries are tortuous or
calcified to a degree that advancement of a delivery
sheath would probably be difficult; and
● any other situation exists that appears likely to make it
difficult to deliver a stent graft or to increase the risk of
complications from TEVAR.
Some stent graft manufacturers have established mor-
phologic indications for TEVAR that are based on the
characteristics of their devices. Moreover, the 2002 Second
International Summit on Thoracic Aorta Endografting
Fig 1. Custom-designed stent grafts for thoracic endovascular
aneurysm repair. Endoprostheses for treating distal arch aneurysms
should have fenestrations to preserve blood flow into the arch
vessels.(Tokyo) reached the following consensus on morphologic
fter d
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landing zone, the diameter of the aorta should preferably
be 40 mm, depending on the radial force of the stent
graft; and to prevent endoleaks and migration, both of
which are likely to result from tortuosity of the aortic arch,
the landing zone on the proximal end must be at least 20
mm long.
Clinical indications. The results of open surgery to
Fig 2. Angiograms show placement of two stent grafts a
into the arch vessels through the fenestrations in the
deployment of the first stent graft. C, Image obtained arepair thoracic aortic aneurysms have been improving, butsurgical mortality remains of concern. Patients at a high risk
of complications are usually excluded from surgery; there-
fore, minimally invasive stent grafting is their only thera-
peutic option. However, TEVAR is also effective in low-
risk patients who meet the morphologic criteria for the
procedure. The consensus of the Second International
Summit on Thoracic Aorta Endografting was that the
primary candidates for TEVAR are high-risk surgical pa-
rom the ascending aorta, with preservation of blood flow
e. A, Predeployment image. B, Image obtained after
eployment of the second stent graft.way f
devictients and elderly people in terms of physiologic reserve
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rience with TEVAR, the patient’s preference, and other
conditions may be considered in choosing between open
surgery and endografting.
Limitations. Currently at our institution, TEVAR is
precluded only by the presence of the morphologic exclu-
sion findings, as described. The stent grafts used in TEVAR
are generally delivered through the descending aorta; if
necessary, we will deliver a device through the ascending
aorta (Fig 2) to repair an aneurysm in the distal aortic arch,
with the aim of achieving optimal long-term results. The
use of precision devices and advanced procedural skills and
techniques should allow deployment of a stent graft almost
anywhere in the aorta. We think TEVAR can be used as
long as the segment of healthy aorta from the origin of the
left common carotid artery to the beginning of the aneu-
rysm is at least 15 mm long.
We sometimes cover the left subclavian artery with a
stent graft to extend the landing zone, but only after
conducting an occlusion test of the left subclavian artery to
assess the safety of this procedure. If bilateral communica-
tion at the basilar artery is insufficient, or treatment of
thoracoabdominal aneurysmal aortic segments requires
multiple intercostal incisions in a wide area, we perform a
bypass operation to the left subclavian artery to maintain
blood flow.
Some physicians think that an aortic dissection with an
entry tear in the descending aorta, including a DeBakey
IIIb retrograde dissection, is a good indication for TEVAR
because it is technically relatively easy to close an entry
tear.18 We do not agree with this view, because the proxi-
mal landing zone in such cases, which is the most critical
area for stent graft deployment, is diseased as a result of the
dissection. In addition, the potential intimal flap, which is
part of the landing zone, may be damaged during stent
graft delivery or may degenerate or over time.
It may appear that a Stanford type B dissection could be
treated by TEVAR, but we have had cases in which the
distal landing zone became diseased, and over time, the end
of the stent graft injured the intimal flap. In other cases, a
false lumen became enlarged when a re-entry tear near the
abdominal branch vessels remained treated. Much addi-
tional research is needed before the role of TEVAR in the
treatment of aortic dissection can be defined.
METHODS
Environment and equipment. The environment for
performing TEVAR varies according to the institution, but
a highly sterile operating room (Fig 3) is desirable. General
anesthesia is preferred in case a conversion to urgent open
surgery is necessary. TEVAR can also be performed in an
angiography suite, which will provide better fluoroscopic
images; in this case the intervention is performed under
local anesthesia. Because general anesthesia has fewer and
fewer complications and a TEVAR procedure may have
serious side effects, including iatrogenic arterial injuries, an
operating room and general anesthesia appear to be safer sothat a necessary conversion to open surgery can be accom-
plished swiftly and smoothly.
To obtain fluoroscopic images, we use an adjustable
13-inch C-arm digital subtraction angiography (DSA) unit
that easily provides a wide range of fluoroscopic coverage.
We have installed an operating table that allows operators
to adjust the position, angle, and height of the unit (Fig 3).
Procedure. Delivery sheaths for stent graft deploy-
ment in TEVAR procedures can be inserted through a
femoral artery, an iliac artery, or a vascular graft anasto-
mosed to an artery. We prefer to use a femoral artery
because it is the easiest vessel to expose. We preferably use
a “tug-of-wire” guiding technique,7 which involves ad-
vancing a long guidewire from the right brachial artery,
capturing it with a snare catheter delivered from the ex-
posed femoral artery, and pulling it through to the femoral
artery.
When deploying the stent graft, particularly at the distal
arch, we take care to push it to make it lie along the greater
curve of the aorta. This helps prevent displacement of the
endoprosthesis. To achieve precise alignment of the fenes-
trated segment of a Najuta stent graft to the three branch
vessels in the aortic arch, we land the device gradually while
using the flow force to facilitate accurate deployment. A
final touch up to oppose the stent graft against the landing
zone is done with an occlusion balloon in areas in which use
of the tug-of-wire method is possible. A final DSA image is
obtained to check for endoleaks and to ascertain whether
deployment of an additional device is required. Follow-up
CT scans are scheduled for 3, 6, and 12 months postoper-
atively and annually thereafter.
RESULTS
Initial results. We performed about 1100 endovascu-
lar procedures to treat thoracic aortic aneurysms between
1995 and February 2008. Of these, 682 cases were per-
formed at Tokyo Medical University, including 474 with-
out a dissection and 208 with a dissection. The aneurysm
Fig 3. Operating theater at Tokyo Medical University, Tokyo,
Japan.was located in an area between the distal arch to the
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were treated with fenestrated stent grafts) and in the de-
scending aorta in 247.
Initial success was defined as an absence of endoleak
and complete thrombosis of the aneurysm on postoperative
CT scanning (Fig 4). The initial success rate was 95.2%.
Complications occurred in 26 patients (3.8%) as a result of
a cerebral infarction caused by an embolism. Most patients
had only mild adverse effects, such as numbness in the
extremities, mild dysarthria, or paresthesias. Six patients
(0.9%) had severe paralysis or changes in consciousness.
Among the 26 patients who had a cerebral infarction,
fenestrated stent grafts had been used in 16; thus, the
cerebral infarction rate in patients who received a fenes-
trated device was 5.5%. There were five serious cerebral
infarctions (1.7%), the rate of paraplegia was 2.6%, and
aortic injury occurred in 1.2% and iliac-femoral artery injury
in 6.0% after placement of a fenestrated device.
Results with the fenestrated stent grafts improved over
time as changes were made to their design. The occurrence
of cerebral infarction increased temporarily when we began
to deliver the devices from the proximal side, then declined
with design improvements; no infarctions have occurred
since 2007. No complications have resulted from throm-
bosis of arch vessels after placement of a fenestrated stent
graft.
Long-term results. A review of the medical records of
patients who had undergone TEVAR at least 2 years earlier
and in whom measurement of the aortic diameter was
possible found that 62% had a reduction in aneurysm
diameter, 33% had no change, and 5% had a diameter
enlargement. Most enlargements occurred in patients with
Fig 4. Computerized tomography scan shows total exclusion of a
distal arch aneurysm, with no endoleaks. A customized fenestrated
stent graft was used.an insufficient landing zone. A second endoleak developedin many of these patients and was treated by insertion of
another stent graft or by open surgery.
Structural damage to the endoprosthesis was observed
in 1.4% of patients, and stent graft migration occurred in
7.0%; no migrations occurred in patients treated with
TEVAR after 2007, probably because of improvements in
device design. The 5-year survival rate was 62.4%, with
follow-up in 96.8% of the patients.
DISCUSSION
For the past 13 years, we have not only treated thoracic
aneurysms endovascularly but have also been involved in
developing better stent grafts, partly by means of evalua-
tions of our treatment experience. We have designed a
variety of TEVAR endoprostheses, focusing particularly on
devices for use in the distal arch, which is especially prone to
aneurysm. Our long-term results suggest that fenestrated
stent grafts provide the most effective and safest results in
this location. In the past we developed prototypes of
branched stent grafts, but we subsequently recognized that
such devices might collapse and occlude because of remod-
eling of the aortic arch over time. This potential safety
problem led us to exclude branched devices from our
development efforts.
The most important factors to consider relative to use
of a fenestrated stent graft to treat aneurysms at the distal
arch are safe and accurate deployment, sealability, and
avoidance of migration during the long term. Achieving
precise alignment of the fenestrated portion of the device to
the arch branch vessels requires control during the delivery
procedure, and this can be enhanced considerably by a
stabilizer. Moreover, using the blood pressure to aid stent
graft deployment and pushing the device in the proximal
direction helps to seat it along the greater aortic curve,
thereby creating a seal that may decrease the risk of migra-
tion over time.
Our stent grafts are partly custom made, with longitu-
dinal stiffness and a precurved shape, and this may also
contribute to accurate deployment and a high long-term
success rate. Cerebral infarction is always a possible compli-
cation of treatment of distal arch aneurysms. One possible
cause of infarction after TEVAR is a release of plaque from
the aortic lumen during advance of the delivery sheath. In
our patients in whom a fenestrated stent graft was used
to treat a distal arch aneurysm, however, the cerebral
infarction rate was 5.5% and the severe infarction rate
was only 1.7%.
TEVAR tends to have a lower rate of serious complica-
tions than open surgery, perhaps because of differences in
the mechanisms of the adverse effects of the two proce-
dures. For example, TEVAR does not require extracorpo-
real circulation; therefore, patients do not have low cerebral
perfusion during the procedure. Moreover, some compli-
cations from stent grafting can be reduced by procedural
changes. Thus, device migration due to an inadequate
proximal landing zone and the development of type I
endoleaks have been addressed by delivering stent grafts
from a more proximal side.
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plicationswithTEVARmay be enhanced by the greater use of
this procedure in challenging patients, such patients who are
elderly or are poor candidates for open surgery. In our series,
this led to a temporary elevation in the cerebral infarction rate
among patients undergoing a distal arch repair. The rate
subsequently decreased with improvements in stent graft de-
sign and procedural techniques.
CONCLUSIONS
The clinical history of TEVAR is still short, and the
learning curve for TEVAR has not yet been reached. Re-
sults are promising overall, but room for improvement
remains for both stent grafts and their peripheral devices. In
addition, long-term durability data are not yet available;
therefore, TEVAR cannot be considered a well-established
treatment method just yet. Future enhancements in oper-
ational success will depend on the ease of use of not only of
stent grafts themselves but also their associated devices,
such as the delivery sheaths. Major advances will require
cooperation between device manufacturers and physicians.
In Japan, the approval of the TAG endoprosthesis for
TEVAR was an important milestone that extended endo-
vascular treatment options beyond abdominal aneurysm
therapy. Achieving wide availability of stent grafts devel-
oped specifically for use in the distal aortic arch will be
another large step toward meeting an urgent need.
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Dr Roy Greenberg (Cleveland, Ohio). I thought that was an
excellent talk, and you have an unbelievable experience that dwarfs
all of the experiences in this country and probably the rest of the
world. I hope that you get a good publication so that we can all
learn from this. I have a question. You had said in the beginning of
your talk how there are 36 different types of the grafts. How do youwhere you put things and how you plan the delivery system and the
device.
Dr Satoshi Kawaguchi. It is a very difficult question and also
difficult for me to decide which types I can use. So we have this
specialist in the hospital to choose the device, so it depends on him.
So I think we have long time to train to work in that part. So it is
very difficult I think.
